SynthesisEuropean journal of nutrition2025
Inverse association between eicosapentaenoic acid and incident colorectal cancer: a dose-response meta-analysis of twenty-six independent prospective cohorts.
Synthesis in European journal of nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeWhile individual n-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) exhibited distinct mechanisms in attenuating colorectal cancer (CRC) progression, their prospective associations with CRC risk remain inconsistent. This study aimed to determine the dose-response relationships between total and individual n-3 PUFAs and incident CRC.
methodsWe systematically searched PubMed, Embase, and Cochrane Library though April 2024 for pertinent prospective cohorts assessing dietary or blood-based n-3 PUFAs in relation to CRC risk. The shape of nonlinear dose-response relationships was modeled using one-stage random-effects meta-analyses. Study-specific risk ratios (RRs) with 95% confidence intervals (CIs) for per unit increase in PUFAs exposure were pooled to assess the strength of linear trends using random-effects inverse-variance weighting meta-analyses.
resultsTwenty-six cohorts were included, comprising 18 dietary cohorts (19,763 events and 1,663,721 participants) and 8 biomarker cohorts (3,443 events and 14,316 participants). Each 100-mg/day increase in EPA intake was slightly associated with 5% reductions in CRC risk (RR: 0.95, 95% CI: 0.91-1.00), whereas no significant association was observed for DHA. A strong inverse linear trend was observed for per 1% increase in circulating LC n-3 PUFA levels (p for linearity < 0.001), with a pooled RR of 0.86 (95% CI: 0.80-0.92) for EPA and 0.95 (95% CI: 0.91-0.99) for DHA.
conclusionCirculating EPA levels demonstrated a significant inverse dose-dependent association with CRC risk. These findings suggest that increasing intake of EPA through diet or supplementation to elevate PUFAs' levels in circulating may contribute to preventing against the incident CRC.
Indexed as
Identifiers
40515761What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.